The $172.5M April equity raise extends cash runway into 2027, de-risking upcoming Phase 2 celiac and Phase 1b vitiligo/alopecia readouts. Fast Track designation adds regulatory momentum. However, the EPS miss and accelerating burn rate cap upside. Monitor topline data catalysts, celiac Phase 2 results are the primary swing factor for the stock.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 15 $23.11entry
- T+1 · 6mo ago −9.26%α −9.20% · $20.97
- T+5 · 6mo ago −6.58%α −7.54% · $21.59
- T+20 · 5mo ago −21.90%α −24.01% · $18.05
- T+60 · 3mo ago +232.63%α +228.11% · $76.87
Price Chart
How similar events traded
Executive Summary
Forte Biosciences reported Q1 2026 net loss of $1.24/share, wider than the $0.98 consensus miss, with no revenue. The key positive is FB102 receiving FDA Fast Track Designation for celiac disease, but the net loss deepened to $22.1M from $15.7M a year ago. A $172.5M April offering (6.6M shares) provides cash runway through upcoming Phase 2 celiac and Phase 1b vitiligo/alopecia readouts.
Key Financial Metrics
Key Facts
- Q1 2026 net loss per share $(1.24) vs consensus $(0.98), a 26.5% miss
- Net loss widened to $22.1M from $15.7M in Q1 2025, driven by R&D spend up 62% to $20.5M
- FB102 received FDA Fast Track Designation for celiac disease
- Cash and equivalents $58.2M at March 31, 2026, supplemented by $172.5M gross April offering (6.6M shares)
- Phase 2 celiac topline data expected in 2026; Phase 1b vitiligo data expected shortly; alopecia areata data in 2026
- Weighted average diluted shares rose 56% YoY to 17.8M, reflecting prior equity raises
Financial Impact
Net loss per share $(1.24) vs consensus $(0.98); R&D spend $20.5M (+62% YoY); cash burn rate ~$22M/quarter pre-April offering
Risk Factors
- Clinical trial failure, Phase 2 celiac data may not replicate Phase 1b positive results
- Dilution, 6.6M new shares from April offering plus 4.0M prefunded warrants overhang
- Cash burn, operating expenses running ~$22M/quarter with no revenue; $58.2M cash pre-offering provides ~2.6 quarters runway without the April raise
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-224214 |
| Document: d95486d8k.htm | 0001193125-26-224214 |
| Document: 0001193125-26-224214-index-headers.html | 0001193125-26-224214 |
| Document: 0001193125-26-224214-index.html | 0001193125-26-224214 |
| Document: 0001193125-26-224214.txt | 0001193125-26-224214 |
| 8-K Data (Synthetic) | 0001193125-26-224214 |
Track record
15 reports on FBRX
2 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +39.79% at T+60 after the Apr 8, 2026 report. 4 of 7 went positive at some point.
Filters
- Nov 13, 20263d ago SC 13G/A Bearish 5/10 Entry price pending
- Nov 13, 20263d ago SC 13G/A Bearish 5/10 Entry price pending
- Nov 4, 202612d ago SC 13G/A Bearish 4/10 No price data
- Sep 2, 202610w ago EFFECT Bearish 7/10 Entry $76.99 settles Nov 27
- Sep 2, 202610w ago EFFECT Bearish 6/10 Entry $76.99 settles Nov 27
- Aug 27, 202611w ago 25-NSE Bearish 9/10 Entry $76.99 settles Nov 20
- Jul 27, 202616w ago 8-K Bullish 8/10 Entry $76.50 No price data
- Jun 11, 202622w ago EFFECT Bearish 6/10 Entry $17.40 No price data
- Jun 5, 202623w ago S-3/A Bearish 6/10 Entry $15.67 No price data
- Jun 2, 202623w ago S-3 Bearish 6/10 Entry $17.00 to $76.99 ▼ −352.88% −350.38% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers